Cannabis for Tremor
An honest look at what cannabis can and can't do for essential tremor, Parkinson's tremor, and other movement disorders.
Cannabis for tremor is one of the most over-hyped indications in medical marijuana marketing. The published trials are small, short, and mostly negative or mixed. THC may modestly reduce tremor in some Parkinson's patients but can worsen balance and cognition. CBD has not been shown to reduce essential tremor in controlled trials. Multiple sclerosis tremor has the weakest data of all. If you try cannabis for tremor, treat it as an experiment with real downsides, not a proven therapy.
Plain-language summary
Tremor is involuntary rhythmic shaking, most often of the hands. The main causes are essential tremor (ET), Parkinson's disease (PD), multiple sclerosis (MS), and dystonia. Cannabis is widely marketed as a tremor treatment, largely on the strength of viral videos and patient testimonials. The actual clinical trial evidence is thin and mostly disappointing.
Short version:
- Parkinson's tremor: A few small studies suggest THC-containing cannabis may modestly reduce tremor in some patients Weak / limited. Other studies show no benefit.
- Essential tremor: A 2022 randomized controlled trial of CBD showed no significant improvement over placebo Weak / limited.
- MS tremor: Cannabis-based medicines like nabiximols help spasticity but have not clearly improved tremor Weak / limited.
This article is not medical advice. Talk to a neurologist before starting, stopping, or substituting any tremor treatment.
What probably works
Honestly: nothing in cannabis has earned a "probably works" rating for tremor.
The closest contender is THC (or THC-dominant cannabis) for Parkinson's tremor, where a small observational study by Lotan et al. (2014) found a reduction in tremor scores 30 minutes after smoking cannabis [1] Weak / limited. But this was open-label, uncontrolled, and small (n=22). It's a signal, not proof.
No cannabinoid has FDA or EMA approval for any tremor indication. Nabiximols (Sativex) is approved in several countries for MS spasticity, not tremor.
What might work
THC for Parkinson's tremor. Beyond the Lotan study, a 2020 randomized crossover trial of cannabis oil (THC/CBD) in PD found improvements in some motor and non-motor symptoms but did not establish a clear tremor-specific benefit [2] Weak / limited. Reviews by the Movement Disorder Society conclude evidence is "insufficient" to recommend cannabis for PD motor symptoms [3] Weak / limited.
Cannabis for sleep and anxiety that worsen tremor. Tremor amplitude often increases with stress and fatigue. If cannabis improves sleep or anxiety in a given patient, tremor may indirectly improve Anecdote. This is a downstream effect, not a direct anti-tremor mechanism, and it's not unique to cannabis.
High-dose CBD for some dystonias. A small 1986 open-label study by Consroe et al. reported modest improvement in dystonic movements with CBD up to 600 mg/day [4] Weak / limited. This has not been replicated in modern controlled trials.
What doesn't work / weak evidence
CBD for essential tremor. The best-designed study to date — a 2022 randomized, double-blind, placebo-controlled crossover trial by Bega et al. of CBD plus a small amount of THC in essential tremor — found no significant reduction in tremor versus placebo, and reported worsened balance and more side effects in the active arm [5] Weak / limited. This is the strongest single piece of evidence in the entire field, and it's negative.
Cannabis for MS tremor. The large CAMS trial (Zajicek et al., 2003) tested cannabis extract and THC in MS and found no objective improvement in tremor on rater-blinded scales, though patients reported subjective benefit [6] Weak / limited. Subsequent reviews echo this: cannabinoids help MS spasticity and pain more than tremor [7].
"Indica strains calm tremor." This is marketing folklore. The indica/sativa distinction does not reliably predict chemistry or clinical effect Disputed. See Indica vs Sativa.
What we don't know
- Whether specific cannabinoid ratios (e.g., 1:1 THC:CBD vs THC-dominant) matter for tremor No data.
- Whether long-term use changes tremor trajectory, for better or worse No data.
- Whether cannabis interacts meaningfully with levodopa, propranolol, primidone, or topiramate in ways that affect tremor control Weak / limited.
- Whether any minor cannabinoid (CBG, CBN, THCV) affects tremor. There are no human trials.
- Whether inhaled vs oral routes differ for tremor specifically. Onset and duration differ, but tremor-relevant comparisons haven't been done.
Comparison with standard treatments
Essential tremor. First-line drugs are propranolol and primidone, each reducing tremor amplitude by roughly 50% in responders [8]. Second-line options include topiramate and gabapentin. For drug-refractory cases, focused ultrasound thalamotomy and deep brain stimulation (DBS) produce large, durable reductions [8]. Against this benchmark, the negative CBD trial result is a meaningful gap.
Parkinson's tremor. Levodopa is the gold standard for most PD motor symptoms; tremor is the most variable to respond. Anticholinergics (trihexyphenidyl) and amantadine help some patients. DBS is highly effective for refractory tremor [9]. Cannabis has not been compared head-to-head with any of these.
MS tremor. No drug is reliably effective; treatment is often physical therapy plus weighted utensils and surgical options (thalamic DBS) in severe cases [10]. Cannabis-based medicines help spasticity and pain but are not a tremor treatment.
In short: standard treatments are imperfect but generally outperform anything cannabis has shown in trials.
Risks
Tremor patients often skew older and may have balance, cognitive, or cardiovascular vulnerabilities. Risks worth weighing:
- Worsened balance and gait. Documented in the Bega ET trial [5] and a known THC effect generally. Falls are a major source of harm in PD and ET populations.
- Cognitive slowing. Particularly relevant in PD, where cognitive impairment is already common.
- Orthostatic hypotension. Both cannabis and PD medications can cause it; combining them risks falls and syncope.
- Drug interactions. CBD inhibits several CYP450 enzymes and can raise levels of drugs metabolized by them.
- Psychiatric effects. THC can precipitate anxiety, paranoia, or psychotic symptoms, more likely in older adults and those with PD-related hallucinations.
- Cost and legality. Medical cannabis is typically not insured; costs accumulate.
If you and your neurologist decide to try cannabis for tremor, sensible practice is: start very low, use a standardized product with a known cannabinoid profile, track tremor with a simple objective measure (spiral drawing, video), and stop if balance or cognition worsens.
This is not medical advice. Decisions about tremor treatment should be made with a qualified clinician familiar with your full history and medications.
Sources
- Peer-reviewed Lotan I, Treves TA, Roditi Y, Djaldetti R. Cannabis (medical marijuana) treatment for motor and non-motor symptoms of Parkinson disease: an open-label observational study. Clinical Neuropharmacology, 2014;37(2):41-44.
- Peer-reviewed Chagas MH, Zuardi AW, Tumas V, et al. Effects of cannabidiol in the treatment of patients with Parkinson's disease: an exploratory double-blind trial. Journal of Psychopharmacology, 2014;28(11):1088-1098.
- Peer-reviewed Bougea A, Koros C, Stamelou M, Stefanis L. Medical cannabis as an alternative therapeutics for Parkinsons' disease: Systematic review. Complementary Therapies in Clinical Practice, 2020;39:101154.
- Peer-reviewed Consroe P, Sandyk R, Snider SR. Open label evaluation of cannabidiol in dystonic movement disorders. International Journal of Neuroscience, 1986;30(4):277-282.
- Peer-reviewed Bega D, Simuni T, Okun MS, Chen X, Schmidt P. Cannabidiol for Essential Tremor: A Randomized, Double-Blinded, Placebo-Controlled Crossover Study. Movement Disorders Clinical Practice, 2022 (and related publications).
- Peer-reviewed Zajicek J, Fox P, Sanders H, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet, 2003;362(9395):1517-1526.
- Peer-reviewed Koppel BS, Brust JC, Fife T, et al. Systematic review: Efficacy and safety of medical marijuana in selected neurologic disorders. Neurology, 2014;82(17):1556-1563.
- Peer-reviewed Zesiewicz TA, Elble RJ, Louis ED, et al. Evidence-based guideline update: treatment of essential tremor: report of the Quality Standards subcommittee of the American Academy of Neurology. Neurology, 2011;77(19):1752-1755.
- Peer-reviewed Fox SH, Katzenschlager R, Lim SY, et al. International Parkinson and Movement Disorder Society Evidence-Based Medicine Review: Update on Treatments for the Motor Symptoms of Parkinson's Disease. Movement Disorders, 2018;33(8):1248-1266.
- Peer-reviewed Mills RJ, Yap L, Young CA. Treatment for ataxia in multiple sclerosis. Cochrane Database of Systematic Reviews, 2007;(1):CD005029.
- Government National Academies of Sciences, Engineering, and Medicine. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. Washington, DC: National Academies Press, 2017.
How this page was made
Generation history
Drafting assistance and fact-check automation are used, with a human operator spot-checking on a weekly basis. See how articles are made.